(CRP) (turbidimetric assay), platelet count (PLT), hemoglobin, and leukocyte count. Serum was stored at -70oC until the analysis of VEGF, EGF, FGFb, and FGFa using a sensitive sandwich enzyme-linked inmunosorbent assay (Human VEGF Immunoassay Quantikine® ELISA kit, Human EGF Immunoassay Quantikine® ELISA kit, Human FGF basic Immunoassay Quantikine® ELISA kit and Human FGF acidic Immunoassay Quantikine® ELISA kit, R&D System, United States). The system uses microplates with the walls coated with a monoclonal antibody and an enzyme-linked polyclonal antibody specific for VEGF, EGF, FGFb, or FGFa. All analyses and calibrations were performed in duplicate and were read using BioTek PowerWaveXS (Biotek Instruments, United States).
Data distributions were assessed using the Shapiro-Wilk test. Data were described as mean ± standard deviation and median (Q1, Q3). We used the rank Spearman's test to calculate correlations. The r values of correlations were determined and corresponding P-values of less than 0.05 were considered significant. The groups were compared using the Mann-Whitney U test and Kruskal-Wallis test. The statistical analysis was performed using the STATISTICA software, version 6.0.
REsuLTs
The clinical and laboratory characteristics of the patients and controls are presented in the TAbLE. Serum VEGF, EGF, FGFb, and FGFa levels were similar between the patient groups and controls (P >0.05) (FIGuREs 1 and 2) .
In the study group, 75 patients were treated with disease-modifying antirheumatic drugs (37 received methotrexate, 2 received methotrexate in combination with cyclosporine A, and 36 received sulfasalazine) and 23 received only hyperostosis, and osteitis) have not been well established yet. Therefore, the aim of this study was to assess the serum levels of selected angiogenic cytokines (VEGF, EGF, FGFb, and FGFa) and their associations with the clinical presentation of patients with PsA and SAPHO syndrome.
PATIENTs ANd mEThOds
The study was approved by the local ethics committee of the Pomeranian Medical University in Szczecin, Poland. Informed consent was obtained from all patients. We studied a total of 98 Caucasian patients, including 80 patients with PsA and 18 with SAPHO. The control group consisted of 20 healthy volunteers matched for age and sex.
The diagnosis of PsA was made according to the CASPAR criteria (Classification Criteria for Psoriatic Arthritis), 20 while the diagnosis of SAPHO syndrome was based on the Kahn criteria. 21 The following data were recorded: age, sex, disease duration, presence of peripheral or axial joint involvement, type of skin psoriasis, nail involvement, and treatment.
In the PsA group, skin changes were assessed according to the Psoriasis Area and Severity Index (PASI). 22 The patient's pain due to the disease at the time of examination was assessed by the visual analogue scale (VAS). We assessed the following indices: Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Global Index (BASG). These indices have a possible score of 0 to 10 with a higher score indicating greater disease activity. We regarded patients as having an active disease if the BASDAI score was higher than 4. [23] [24] [25] [26] Blood was taken for the assessment of erythrocyte sedimentation rate, C-reactive protein Data are presented as number or mean ± standard deviation (Q1, Q3).
Abbreviations: CRP -C-reactive protein, EGF -epidermal growth factor, ESR -erythrocyte sedimentation rate, FGFa -acidic fibroblast growth factor, FGFb -basic fibroblast growth factor, PASI -Psoriasis Area and Severity Index, SD -standard deviation, VAS -visual analogue scale, VEGF -vascular endothelial growth factor, WBC -white blood count EGF levels were found between patients with the peripheral and axial forms of the disease (P = 0.56 and P = 0.28, respectively). In the group of 64 patients with peripheral arthritis, there were no differences between the subgroups of patients with polyarthritis, oligoarthritis, and distal arthritis in terms of ESR, CRP, VEGF, EGF, FGFb, and FGFa levels (all P >0.05).
In the PsA group, serum VEGF levels were positively correlated with CRP levels (P = 0.04), the BASFI score (P = 0.03), and disease duration (P = 0.007). There were no correlations between serum VEGF levels and PLT, ESR, BASDAI, BASMI, BASG, VAS, or age (all P >0.05).
No correlations were found in the PsA group between EGF and CRP, ESR, PLT, BASDAI, BASFI, BASMI, BASG, VAS, age, or disease duration (all P >0.05). Moreover, no differences were found in this group between the subgroups of patients receiving different treatments in terms of VEGF and EGF levels (P >0.05).
Only 9 patients (11.3%) with PsA had measurable FGFb levels (above 0 ng/ml) and only 18 (22.5%) had detectable FGFa levels (above 0 ng/ml).
In patients with SAPHO syndrome, 17 patients had palmoplantar pustulosis and 1 patient had severe acne. No significant correlations were observed between VEGF and EGF levels and CRP, ESR, PLT, BASDAI, BASFI, BASMI, BASG, VAS, age, or disease duration (all P >0.05). We did not calculate correlations for FGFb and FGFa in the SAPHO group because only 1 patient (5.6%) had FGFb levels over 0 ng/ml and only 4 patients (22.2%) had FGFa levels over 0 ng/ml. No differences were found in this group between the subgroups of various treatment regimens in terms of VEGF (P = 0.99; FIGuRE 3) and EGF levels (P = 0.80; FIGuRE 4). dIsCussION There are scarce data in the literature regarding a potential role of serum VEGF in disease pathogenesis and its correlations with disease activity in patients with PsA.
3,4,6,7 Moreover, no data have been found for the serum levels of VEGF or other angiogenic cytokines in SAPHO syndrome. On the other hand, there are data available on serum VEGF levels in RA patients.
7,8,10,11
Serum VEGF may be derived from a number of sources including neutrophils, synovial fluid, inflamed synovial tissue, and platelets.
1,2 The presence of VEGF has been demonstrated in serum, synovial membrane, and synovial fluid in patients with RA. In these patients, VEGF is produced by neutrophils and its concentration in the synovial fluid is correlated with disease activity. However, no correlations have been shown between VEGF concentrations in the synovial fluid and those in serum in patients with RA.
2, 7 In these patients, serum VEGF is correlated with the markers of acute disease and the number of swollen and tender joints. Previous studies reported higher serum VEGF levels in early disease in patients with RA. 7 nonsteroidal anti-inflammatory drugs. No patients received biological therapy.
In the PsA group, no differences were found between women and men in terms of VEGF levels (P = 0.35) or EGF levels (P = 0.225). All patients in this group had plaque-type psoriasis. No correlations were found in this group between the PASI score and the levels of VEGF (P = 0.91), EGF (P = 0.63), FGFb (P = 0.48), or FGFa (P = 0.27).
Nail psoriasis was present in 52 patients (65%). No differences were found between patients with and without nail psoriasis in terms of VEGF or EGF levels (P = 0.32 and P = 0.85, respectively).
In the PsA group, 64 patients had peripheral arthritis (44 had polyarthritis, 15 had oligoarthritis, and 5 had distal arthritis) and 16 patients had axial disease. No differences in the VEGF or the differences in their concentrations in serum and synovial fluid. The formation of new vessels plays an important role in the inflammatory process in the course of sacroilitis and enthesitis in ankylosing spondylitis. 4 Angiogenesis also plays a role in bone formation, especially in diseases characterized by bone formation. 2,4 Angiogenesis is stimulated by VEGF. Goldberger et al. 5 reported a positive correlation between serum VEGF levels and the BASMI in patients with ankylosing spondylitis. The absence of differences in serum VEGF levels in PsA patients with peripheral arthritis and axial disease could suggest the potential role of VEGF in synovitis and enthesitis.
In the PsA group, the lack of correlations between the markers of angiogenesis and the PASI score could be partly explained by low severity of skin lesions (mean PASI score, 7.1).
No differences between the patient groups and controls in terms of serum concentrations of angiogenic cytokines could be explained by low activity of the disease following treatment that might have affected serum concentrations of angiogenic cytokines and resulted in a decrease of their levels.
No differences between the subgroups of various treatment regimens in terms of VEGF and EGF levels could be explained by the effectiveness of treatment.
We were unable to demonstrate a relationship between the concentrations of various angiogenic cytokines and the parameters of disease activity in the SAPHO group. This may due to the small size of the group.
Our study has several limitations including a small number of study patients (especially in the SAPHO group) and no group of patients without treatment.
In conclusion, our data suggest a role of VEGF in PsA. Further studies are required to better understand the role of angiogenic cytokines in PsA.
Drouart et al.
4 demonstrated a positive correlation between serum VEGF levels and disease activity indices, such as BASDAI, ESR, and CRP in ankylosing spondylitis and PsA. In our study, we observed a correlation between serum VEGF levels and CRP only in patients with PsA. Additionally, we examined patients with SAPHO syndrome. However, no correlations were found in these patients, which may result from the small size of the group. In this study, the lack of correlations between the markers of angiogenesis and other markers of disease activity could be due to 
